Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of “Buy” from Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have earned an average recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $8.00.

A number of equities analysts have weighed in on the company. D. Boral Capital decreased their target price on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, March 25th. Wall Street Zen lowered Quince Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Finally, Oppenheimer assumed coverage on Quince Therapeutics in a research note on Monday, March 24th. They issued an “outperform” rating and a $10.00 target price on the stock.

Institutional Investors Weigh In On Quince Therapeutics

Large investors have recently made changes to their positions in the company. Ieq Capital LLC purchased a new position in shares of Quince Therapeutics during the first quarter valued at approximately $1,073,000. Virtu Financial LLC boosted its position in shares of Quince Therapeutics by 48.4% during the first quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock valued at $58,000 after buying an additional 14,128 shares during the period. Intellectus Partners LLC purchased a new position in shares of Quince Therapeutics during the first quarter valued at approximately $71,000. Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics during the fourth quarter valued at approximately $57,000. Finally, Shay Capital LLC boosted its position in shares of Quince Therapeutics by 60.8% during the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock valued at $518,000 after buying an additional 104,616 shares during the period. 30.75% of the stock is owned by institutional investors.

Quince Therapeutics Stock Performance

Shares of Quince Therapeutics stock opened at $1.03 on Friday. The business’s fifty day simple moving average is $1.08 and its 200 day simple moving average is $1.48. The firm has a market capitalization of $46.83 million, a P/E ratio of -0.83 and a beta of 0.83. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33.

Quince Therapeutics (NASDAQ:QNCX) last issued its earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). As a group, analysts anticipate that Quince Therapeutics will post -1.21 EPS for the current year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.